Latest on Ultrasound Renal Denervation
Published: 22 June 2022
4m 2sPart 1 | Session 1 The Science of Ultrasound Renal Denervation: Introduction Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
9m 18sPart 1 | Session 2 Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Andrew Wu
15m 10sPart 1 | Session 3 Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Michael Joner
18m 36sPart 1 | Session 4 RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud Felix Mahfoud
10m 14sPart 1 | Session 5 Panel Discussion: All Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
15m 15sPart 2 | Session 1 The Paradise uRDN System: Dr Andrew Sharp Andrew SP Sharp
9m 57sPart 2 | Session 2 uRDN Clinical Evidence - What does this mean for the field?: Prof Felix Mahfoud Felix Mahfoud
21m 53sPart 2 | Session 3 How to build uRDN centre / therapy pathway: Prof Roland Schmieder Roland E Schmieder
19m 35sPart 3 | Session 1 Introduction and "Ultrasound RDN - Reviewing the Latest Clinical Results" : Atul Pathak Joost Daemen, Atul Pathak, Joachim Weil
11m 41sPart 3 | Session 2 "Ultrasound RDN - Reviewing the Latest Clinical Results" : Joost Daemen Joost Daemen, Atul Pathak, Joachim Weil
28m 37sPart 3 | Session 3 "How to build Interventional HTN Therapy/Practice": Joachim Weil Joost Daemen, Atul Pathak, Joachim Weil
5m 12sPart 4 | Session 1 RADIANCE II Pivotal Trial Ajay J Kirtane
5m 10sPart 5 | Session 1 EuroPCR 2022 – Patient-Level Pooled Analysis of RADIANCE-HTN SOLO and TRIO Trials Ajay J Kirtane
4m 44sPart 5 | Session 2 TCT 2021 – RADIANCE-HTN TRIO 6 months Outcomes vs Sham Procedure for Resistant Hypertension Ajay J Kirtane
16m 20sPart 5 | Session 3 ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane Ajay J Kirtane, Harriette Van Spall
5m 47sPart 5 | Session 4 EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial Ajay J Kirtane
12m 13sPart 6 Ultrasound Renal Denervation – Patient Perspective, Referral Development Melvin D Lobo
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.
This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.
The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
What you will learn:
- How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
- The clinical evidence supporting uRDN and its implications for the field of hypertension
- The process for building a uRDN centre and therapy network
This page is designed for:
- Interventional cardiologists
- General cardiologists
- Hypertension specialists
- Interventional radiologists
More from this programme
The Science of uRDN
The Evidence for uRDN
From Proof to Practice – Treating Hypertension With uRDN
RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension
Results From the Latest Clinical Trials
Patient Perspective & Provider Referral Development
Professor of Medicine
Dr Weber is Professor of Medicine and Associate Dean for Research at the SUNY Downstate College of Medicine in Brooklyn, New York. He received his medical degree from Sydney University in Australia. His career has been focused primarily on hypertension and preventive cardiology.
Dr Weber was one of the founders of The American Society of Hypertension and has served as its President. He is a Fellow of the American College of Physicians, the American College of Cardiology, and the American Heart Association.
Dr Weber's main research interests include the role of the renin-angiotensin system in the genesis of hypertension and as a major factor in cardiovascular prognosis.
Associate Professor and Senior Physician
Prof Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Prof Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.
Ajay J Kirtane
Professor of Clinical Medicine
Ajay J Kirtane, is Professor of Medicine at the Columbia University Medical Center (CUMC) and Director of the Cardiac Catheterization Laboratories at NewYork-Presbyterian (NYP) Hospital / CUMC. Dr. Kirtane is an internationally-renowned leader in Interventional Cardiology, specializing in the care of patients with complex coronary and peripheral vascular disease.
In addition to his clinical commitments, Ajay has a strong interest in clinical education and research, serving as Chief Academic Officer of Columbia Interventional Cardiovascular Care. He is a director of the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics conference, has served as a director of several international, national, and regional educational conferences, and has participated on the program committees for the scientific sessions of both the American College of Cardiology and American Heart Association. Ajay’s research…
Dr Bloch is an Associate Professor, Department of Internal Medicine at University of Nevada School of Medicine and also Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Medical Center Institute for Heart and Vascular Health.
His undergraduate degree is from Princeton University, and he earned his medical degree from Georgetown University Medical School in Washington, DC.
Dr Bloch is also Fellow in the American College of Physicians, the American Society of Hypertension, the National Lipid Association, and the Society of Vascular Medicine.